Efficacy, safety, and patient satisfaction of norditropin and sogroya in patients with growth hormone deficiency: a systematic review and meta-analysis of randomized controlled trials.

What It Covers

This meta-analysis looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Growth hormone deficiency occurs when the pituitary gland does not produce enough growth hormone.

Norditropin®, a recombinant human growth hormone, and Sogroya®, an albumin-binding growth hormone derivative, are prescribed for patients with growth hormone deficiency.

Who the Included Studies Covered

The age groups tagged for this paper are children and adults.

The researchers systematically searched PubMed, Web of Science, and Scopus databases to identify eligible comparative studies.

Their outcomes for children included height velocity and height velocity standard deviation score.

How the Review Was Done

All studies published until June 2023 were included in their analysis.

In contrast, adult outcomes included adverse events, insulin-like growth factor 1-standard deviation score (IGF-1 SDS), and the Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9).

What Was Measured

The subject headings attached to it are Human Growth Hormone, Patient Satisfaction, Randomized Controlled Trials as Topic, Recombinant Proteins, Body Height and Growth Disorders.

The authors tagged it with the keywords Norditropin, RCT, Sogroya, growth hormone deficiency, meta-analysis and systematic review.

What This Means in Plain Language

This is a meta-analysis of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Endocrine), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.